0.00Open0.10Pre Close0 Volume81 Open Interest2.00Strike Price0.00Turnover0.00%IV7.69%PremiumFeb 21, 2025Expiry Date0.00Intrinsic Value100Multiplier64DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma19.50Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Brainstorm Cell Therapeutics Stock Discussion
@MARKET-TEST-DUMMY 48 hours ago.
BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology
Tuesday, 3rd December at 7:00 am
NEW YORK, Dec. 3, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it has received Notice of Allowance from the U.S. Patent & Trademark Office (USPTO) for patent applica...
No comment yet